BACKGROUND: Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade. The dual mechanism inhibitor SCH772984 has shown promising preclinical activity across various BRAFV600/RAS-mutant cancer cell lines and human cancer xenografts. METHODS: We have developed an orally bioavailable ERK inhibitor, MK-8353; conducted preclinical studies to demonstrate activity, pharmacodynamic endpoints, dosing, and schedule; completed a study in healthy volunteers (P07652); and subsequently performed a phase I clinical trial in patients with advanced solid tumors (MK-8353-001). In the P07652 study, MK-8353 was administered as a single dose in 10- to 400-mg dose cohorts, whereas in the MK-8353-001 study, MK-8353 was administered in 100- to 800-mg dose cohorts orally twice daily. Safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity were analyzed. RESULTS: MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models. Forty-eight patients were enrolled in the P07652 study, and twenty-six patients were enrolled in the MK-8353-001 study. Adverse events included diarrhea (44%), fatigue (40%), nausea (32%), and rash (28%). Dose-limiting toxicity was observed in the 400-mg and 800-mg dose cohorts. Sufficient exposure to MK-8353 was noted that correlated with biological activity in preclinical data. Three of fifteen patients evaluable for treatment response in the MK-8353-001 study had partial response, all with BRAFV600-mutant melanomas. CONCLUSION: MK-8353 was well tolerated up to 400 mg twice daily and exhibited antitumor activity in patients with BRAFV600-mutant melanoma. However, antitumor activity was not particularly correlated with pharmacodynamic parameters. TRIAL REGISTRATION: ClinicalTrials.gov NCT01358331. FUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., and NIH (P01 CA168585 and R35 CA197633).
BACKGROUND: Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade. The dual mechanism inhibitor SCH772984 has shown promising preclinical activity across various BRAFV600/RAS-mutant cancer cell lines and humancancer xenografts. METHODS: We have developed an orally bioavailable ERK inhibitor, MK-8353; conducted preclinical studies to demonstrate activity, pharmacodynamic endpoints, dosing, and schedule; completed a study in healthy volunteers (P07652); and subsequently performed a phase I clinical trial in patients with advanced solid tumors (MK-8353-001). In the P07652 study, MK-8353 was administered as a single dose in 10- to 400-mg dose cohorts, whereas in the MK-8353-001 study, MK-8353 was administered in 100- to 800-mg dose cohorts orally twice daily. Safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity were analyzed. RESULTS:MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models. Forty-eight patients were enrolled in the P07652 study, and twenty-six patients were enrolled in the MK-8353-001 study. Adverse events included diarrhea (44%), fatigue (40%), nausea (32%), and rash (28%). Dose-limiting toxicity was observed in the 400-mg and 800-mg dose cohorts. Sufficient exposure to MK-8353 was noted that correlated with biological activity in preclinical data. Three of fifteen patients evaluable for treatment response in the MK-8353-001 study had partial response, all with BRAFV600-mutant melanomas. CONCLUSION:MK-8353 was well tolerated up to 400 mg twice daily and exhibited antitumor activity in patients with BRAFV600-mutant melanoma. However, antitumor activity was not particularly correlated with pharmacodynamic parameters. TRIAL REGISTRATION: ClinicalTrials.gov NCT01358331. FUNDING: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., and NIH (P01 CA168585 and R35 CA197633).
Entities:
Keywords:
Cancer; Clinical Trials; Melanoma; Oncology; Signal transduction
Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245
Authors: Donglu Zhang; Theodore J Chando; Donald W Everett; Christopher J Patten; Shangara S Dehal; W Griffith Humphreys Journal: Drug Metab Dispos Date: 2005-08-23 Impact factor: 3.922
Authors: Tikvah K Hayes; Nicole F Neel; Chaoxin Hu; Prson Gautam; Melissa Chenard; Brian Long; Meraj Aziz; Michelle Kassner; Kirsten L Bryant; Mariaelena Pierobon; Raoud Marayati; Swapnil Kher; Samuel D George; Mai Xu; Andrea Wang-Gillam; Ahmed A Samatar; Anirban Maitra; Krister Wennerberg; Emanuel F Petricoin; Hongwei H Yin; Barry Nelkin; Adrienne D Cox; Jen Jen Yeh; Channing J Der Journal: Cancer Cell Date: 2015-12-24 Impact factor: 31.743
Authors: Matteo S Carlino; Jason R Todd; Kavitha Gowrishankar; Branka Mijatov; Gulietta M Pupo; Carina Fung; Stephanie Snoyman; Peter Hersey; Georgina V Long; Richard F Kefford; Helen Rizos Journal: Mol Oncol Date: 2014-01-15 Impact factor: 6.603
Authors: Ana Herrero; Adán Pinto; Paula Colón-Bolea; Berta Casar; Mary Jones; Lorena Agudo-Ibáñez; Rebeca Vidal; Stephan P Tenbaum; Paolo Nuciforo; Elsa M Valdizán; Zoltan Horvath; Laszlo Orfi; Antonio Pineda-Lucena; Emilie Bony; Gyorgy Keri; Germán Rivas; Angel Pazos; Rafael Gozalbes; Héctor G Palmer; Adam Hurlstone; Piero Crespo Journal: Cancer Cell Date: 2015-08-10 Impact factor: 31.743
Authors: Ryan J Sullivan; Jeffrey R Infante; Filip Janku; Deborah Jean Lee Wong; Jeffrey A Sosman; Vicki Keedy; Manish R Patel; Geoffrey I Shapiro; James W Mier; Anthony W Tolcher; Andrea Wang-Gillam; Mario Sznol; Keith Flaherty; Elizabeth Buchbinder; Richard D Carvajal; Anna M Varghese; Mario E Lacouture; Antoni Ribas; Sapna P Patel; Gary A DeCrescenzo; Caroline M Emery; Anna L Groover; Saurabh Saha; Mary Varterasian; Dean J Welsch; David M Hyman; Bob T Li Journal: Cancer Discov Date: 2017-12-15 Impact factor: 39.397
Authors: Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding Journal: Nature Date: 2013-10-17 Impact factor: 49.962
Authors: Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman Journal: Expert Rev Precis Med Drug Dev Date: 2021-08-11
Authors: Sobhana Babu Boga; Yongqi Deng; Liang Zhu; Yang Nan; Alan B Cooper; Gerald W Shipps; Ronald Doll; Neng-Yang Shih; Hugh Zhu; Robert Sun; Tong Wang; Sunil Paliwal; Hon-Chung Tsui; Xiaolei Gao; Xin Yao; Jagdish Desai; James Wang; Abdul Basit Alhassan; Joseph Kelly; Mehul Patel; Kiran Muppalla; Subrahmanyam Gudipati; Li-Kang Zhang; Alexei Buevich; David Hesk; Donna Carr; Priya Dayananth; Stuart Black; Hong Mei; Kathleen Cox; Bradley Sherborne; Alan W Hruza; Li Xiao; Weihong Jin; Brian Long; Gongjie Liu; Stacey A Taylor; Paul Kirschmeier; William T Windsor; Robert Bishop; Ahmed A Samatar Journal: ACS Med Chem Lett Date: 2018-06-14 Impact factor: 4.345
Authors: Marcelo V Negrao; Victoria M Raymond; Richard B Lanman; Jacqulyne P Robichaux; Junqin He; Monique B Nilsson; Patrick K S Ng; Bianca E Amador; Emily B Roarty; Rebecca J Nagy; Kimberly C Banks; Viola W Zhu; Chun Ng; Young Kwang Chae; Jeffrey M Clarke; Jeffrey A Crawford; Funda Meric-Bernstam; Sai-Hong Ignatius Ou; David R Gandara; John V Heymach; Trever G Bivona; Caroline E McCoach Journal: J Thorac Oncol Date: 2020-06-13 Impact factor: 15.609